Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.74 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.74 |
| ▸ | RECQL | P46063 | 4/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.74 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | HTR2A | P28223 | 2/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.74 |
| ▸ | EGFR | P00533 | 2/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.74 |
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069483 | 1.00 | ALOX15 (0.74) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL21729924 | 1.00 | ALOX15 (0.74) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL13661903 | 1.00 | ALOX15 (0.74) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Hydrochloric Acid SCHEMBL20765475 | 0.98 | ALOX15 (0.72) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Hydrochloric Acid SCHEMBL20764445 | 0.98 | ALOX15 (0.72) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL27853956 | 0.86 | SLC7A5 (0.93) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL30777603 | 0.86 | SLC7A5 (0.93) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL11000382 | 0.85 | SLC7A5 (1.00) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL116907 | 0.85 | SLC7A5 (1.00) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL704089 | 0.85 | SLC7A5 (1.00) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114171847-B | High-flame-retardance high-wettability lithium ion battery diaphragm and preparation method thereof | 江苏厚生新能源科技有限公司 | 2023-09-01 | — | — | CN | claimed |
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12424305-B2 | Closed-loop AI-optimized EMF treatment and digital delivery of data | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2025-09-23 | — | — | US | disclosed |
| CN-120076785-A | Cosmetic composition for inducing melanin synthesis in individuals or animals, preparation method, cosmetic method and use | 科曼宁有限责任公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4532699-A1 | TRIPLE TISSUE CULTURE FUSION | IMBA-Institut für Molekulare Biotechnologie GmbH (AT) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2023233002-A1 | TRIPLE TISSUE CULTURE FUSION | IMBA - INSTITUT FÜR MOLEKULARE BIOTECHNOLOGIE GMBH (AT) | 2023-12-07 | — | — | WO | disclosed |
| CN-105392500-B | Imaging neurological diseases | 通用电气健康护理有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2023117812-A1 | MEMBRANE COATED WITH POLYDOPAMINE AND CHONDROITIN AND PROCESS FOR PRODUCING SAME | GAMBRO LUNDIA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-11498896-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| CN-111647279-B | Aging-resistant functionalized montmorillonite modified asphalt and preparation method thereof | 长沙理工大学 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021044420-A1 | LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF | NEURODERM, LTD. (IL) | 2021-03-11 | — | — | WO | disclosed |
| WO-2020035853-A1 | PROCESS FOR PREPARING PURIFIED LEVODOPAMIDE FREE BASE | NEURODERM, LTD. (IL) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035853-A1 | PROCESS FOR PREPARING PURIFIED LEVODOPAMIDE FREE BASE | NEURODERM, LTD. (IL) | 2020-02-20 | — | — | WO | disclosed |
| WO-2019038639-A1 | CRYSTALLINE LEVODOPA AMIDE FREE BASE AND METHODS OF MAKING AND USING SAME | NEURODERM LTD (IL) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038637-A1 | CRYSTALLINE SALT FORMS OF LEVODOPA AMIDE AND METHODS OF MAKING AND USING SAME | NEURODERM LTD (IL) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038638-A1 | PROCESS FOR PREPARING PURIFIED LEVODOPA AMIDE | NEURODERM LTD (IL) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038638-A1 | PROCESS FOR PREPARING PURIFIED LEVODOPA AMIDE | NEURODERM LTD (IL) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498896-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | ALOX15 2824/4885KDM4E 4204/4885HIF1A 2707/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | ALOX15 1210/4885KDM4E 3787/4885HIF1A 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.